Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase

References

• Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–2765. doi:10.1200/JCO.2008.20.8983
   PubMed Web of Science ®Google Scholar
• Sasaki K, Jabbour E, Short NJ, et al. Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021;96(6):650–658. doi:10.1002/ajh.26156
   PubMed Web of Science ®Google Scholar
• Katz AJ, Chia VM, Schoonen WM, et al. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015;26(11):1627–1642. doi:10.1007/s10552-015-0657-6
   PubMed Web of Science ®Google Scholar
• Gokbuget N. Treatment of older patients with acute lymphoblastic Leukaemia. Drugs Aging. 2018;35(1):11–26. doi:10.1007/s40266-017-0503-5
   PubMed Web of Science ®Google Scholar
• Jammal N, et al. Management of acute lymphoblastic leukemia in older adults. Clin Adv Hematol Oncol. 2022;20(3):161–168.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Sanz M-A, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843–1849. doi:10.1200/JCO.2007.13.7265
   PubMed Web of Science ®Google Scholar
• Stengel A, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood. 2014;124(2):251–258. doi:10.1182/blood-2014-02-558833
   PubMed Web of Science ®Google Scholar
• Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic Leukemia in adults. J Clin Oncol. 2017;35(4):394–401. doi:10.1200/JCO.2016.69.0073
   PubMed Web of Science ®Google Scholar
• Roberts KG. The biology of Philadelphia chromosome-like ALL. Best Pract Res Clin Haematol. 2017;30(3):212–221. doi:10.1016/j.beha.2017.07.003
   PubMed Web of Science ®Google Scholar
• Aldoss I, Stein AS. Advances in adult acute lymphoblastic leukemia therapy. Leuk Lymphoma. 2018;59(5):1033–1050. doi:10.1080/10428194.2017.1354372
   PubMed Web of Science ®Google Scholar
• Siegel SE, Stock W, Johnson RH, et al. Pediatric-inspired treatment regimens for adolescents and young adults with philadelphia chromosome-negative acute Lymphoblastic Leukemia: a review. JAMA Oncol. 2018;4(5):725–734. doi:10.1001/jamaoncol.2017.5305
   PubMed Web of Science ®Google Scholar
• Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91(8):819–823. doi:10.1002/ajh.24419
   PubMed Web of Science ®Google Scholar
• Testi AM, Canichella M, Vitale A, et al. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. Am J Hematol. 2021;96(3):292–301. doi:10.1002/ajh.26066
   PubMed Web of Science ®Google Scholar
• Ferrari LC, Rivas MM, Navickas AB, et al. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients. Ann Hematol. 2023;102(5):1087–1097. doi:10.1007/s00277-023-05151-3
   PubMed Web of Science ®Google Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335–342. doi:10.1038/sj.leu.2401310
   PubMed Web of Science ®Google Scholar
• Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554–563. doi:10.1097/MPH.0b013e3181e6f003
   PubMed Web of Science ®Google Scholar
• Sallan SE, Gelber RD, Kimball V, et al. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990;33:459–466.
   PubMedGoogle Scholar
• Ribera JM, García O, Oriol A, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016;41:12–20. doi:10.1016/j.leukres.2015.11.012
   PubMed Web of Science ®Google Scholar
• O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097–2101. doi:10.1002/cncr.23819
   PubMed Web of Science ®Google Scholar
• Martell MP, Atenafu EG, Minden MD, et al. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. Br J Haematol. 2013;163(4):458–464. doi:10.1111/bjh.12561
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556–1564.
   PubMed Web of Science ®Google Scholar
• Islam N, Rahman MM, Aziz MA, et al. Outcome of adult acute lymphoblastic leukaemia following induction chemotherapy with modified MRC UKALL XII/ECOG E2993 protocol. Bangladesh Med Res Counc Bull. 2012;38(2):43–46. doi:10.3329/bmrcb.v38i2.12879
   PubMedGoogle Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911–918. doi:10.1200/JCO.2008.18.6916
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, El Dika I, Massoud R, et al. Hyper-CVAD compared With BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. a retrospective single-center analysis. Clin Lymphoma Myeloma Leuk. 2017;17(3):179–185. doi:10.1016/j.clml.2016.11.002
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526–534. doi:10.1038/leu.2014.229
   PubMed Web of Science ®Google Scholar
• Buyukasik Y, Acar K, Kelkitli E, et al. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study. Acta Haematol. 2013;130(3):199–205. doi:10.1159/000351172
   PubMed Web of Science ®Google Scholar
• Alacacioglu I, Medeni SS, Ozsan GH, et al. Is the BFM regimen feasible for the treatment of adult acute lymphoblastic leukemia? A retrospective analysis of the outcomes of BFM and hyper-CVAD chemotherapy in two centers. Chemotherapy. 2015;60(4):219–223. doi:10.1159/000375258
   Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157(4):463–471. doi:10.1111/j.1365-2141.2012.09095.x
   PubMed Web of Science ®Google Scholar
• Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146(1):76–85. doi:10.1111/j.1365-2141.2009.07712.x
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375–380. doi:10.1111/ejh.12600
   PubMed Web of Science ®Google Scholar
• Bade NA, Lu C, Patzke CL, et al. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. J Oncol Pharm Pract. 2020;26(1):74–92. doi:10.1177/1078155219838316
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–2253. doi:10.3109/10428194.2011.596963
   PubMed Web of Science ®Google Scholar
• Luskin MR. Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy? Hematology Am Soc Hematol Educ Program. 2021;2021(1):7–14. doi:10.1182/hematology.2021000226
   PubMedGoogle Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. doi:10.1016/S1470-2045(14)71170-2
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Su Y, Jabbour EJ, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151–2160. doi:10.1002/cncr.31317
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi:10.1056/NEJMoa1609783
   PubMed Web of Science ®Google Scholar
• Schuh A. Longitudinal therapeutic drug monitoring to optimize pegaspargase dosing in adults with acute lymphoblastic leukemia (all). EHA congress 2022. Abstract: EP407. 2020.
   Google Scholar
• Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677–1690. doi:10.1016/S1470-2045(15)00363-0
   PubMed Web of Science ®Google Scholar
• Chen R, Atenafu EG, Seki J, et al. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2023;201(4):645–652. doi:10.1111/bjh.18683
   PubMed Web of Science ®Google Scholar
• Burke PW, Hoelzer D, Park JH, et al. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion. ESMO Open. 2020;5(5):e000858.
   PubMed Web of Science ®Google Scholar
• Douer D, Gökbuget N, Stock W, et al. Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022;53:100908. doi:10.1016/j.blre.2021.100908
   PubMed Web of Science ®Google Scholar
• Ribera JM, Morgades M, Montesinos P, et al. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(7):1634–1643. doi:10.1080/10428194.2017.1397661
   PubMed Web of Science ®Google Scholar
• Liang J, Shi P, Guo X, et al. A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. Oncol Lett. 2018;15(1):75–82.
   PubMed Web of Science ®Google Scholar
• Derman BA, Streck M, Wynne J, et al. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(3):614–622. doi:10.1080/10428194.2019.1680839
   PubMed Web of Science ®Google Scholar
• Patel AA, Heng J, Dworkin E, et al. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem. 2021;2(3):413–420. doi:10.1002/jha2.224
   PubMedGoogle Scholar